<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial therapy of prosthetic valve endocarditis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial therapy of prosthetic valve endocarditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antimicrobial therapy of prosthetic valve endocarditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adolf W Karchmer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vivian H Chu, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Issues related to the antimicrobial therapy of prosthetic valve infective endocarditis (IE) will be reviewed here; the content reflects American and European guidelines [<a href="#rid1">1,2</a>]. </p><p>An overview of the management of IE in adults is presented separately. (See  <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults"</a>.)</p><p>General issues related to echocardiography are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5323.html" rel="external">"Role of echocardiography in infective endocarditis"</a>.)</p><p>Issues related to clinical manifestations and diagnosis of prosthetic valve endocarditis, complications of IE, and indications for surgery are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">"Complications and outcome of infective endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>.)</p><p>Issues related to management of native valve endocarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">"Surgery for left-sided native valve infective endocarditis"</a>.)</p><p>Issues related to management of cardiac device infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">"Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/116021.html" rel="external">"Infections involving cardiac implantable electronic devices: Treatment and prevention"</a>.)</p><p>Issues related to management of mycotic aneurysm and brain abscess are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">"Overview of infected (mycotic) arterial aneurysm"</a> and  <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">"Treatment and prognosis of bacterial brain abscess"</a>.)</p><p class="headingAnchor" id="H667370356"><span class="h1">GENERAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Management of prosthetic heart valve infection can be challenging; optimal treatment requires [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Identification of the causative microorganism and selection of an effective bactericidal antimicrobial regimen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for complications of prosthetic valve endocarditis (PVE) (see  <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">"Complications and outcome of infective endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults", section on 'Echo monitoring during therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessing for indications for surgical intervention, particularly when infection has extended beyond the valve to contiguous cardiac tissue, resulting in abscess formation or valve dysfunction (see  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>)</p><p></p><p class="headingAnchor" id="H844595365"><span class="h2">Site of care</span><span class="headingEndMark"> — </span>Treatment for PVE should be initiated in the hospital, preferably in an institution where cardiac surgery is available. This is important because treatment of PVE with antimicrobial therapy alone often fails, particularly when infection occurs within the initial six months after valve surgery, is caused by a virulent organism, or is complicated by paravalvular extension or by valve dysfunction.</p><p>The approach to antibiotic therapy is the same for PVE involving surgically implanted valves and transcatheter implanted aortic valves (TAVI). Among patients with an infected TAVI, 80 percent have one or more clinically evident indications for cardiac surgery; however, only 19 percent of these patients undergo surgical explantation [<a href="#rid3">3</a>]. Most of these patients have not undergone cardiac surgery due to high anticipated surgical mortality; however, as TAVI infections occur in younger patients with fewer comorbidities, surgical intervention will become a more frequent component of management. </p><p>Patients should remain hospitalized until fever resolves and it is clear that surgery can be safely avoided (or, if patients have undergone surgery, that they are stable postoperatively). After initial treatment in the hospital (with resolution of fever and bacteremia, imaging assessment to exclude paravalvular infection, and evaluation regarding the potential need for surgical intervention), consideration may be given to completion of antibiotic therapy in the setting of closely supervised outpatient management. (See <a class="local">'Completing therapy'</a> below.)</p><p class="headingAnchor" id="H126365347"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>For hemodynamically stable patients with an indolent clinical course, antibiotic therapy should be delayed pending blood culture results. This delay allows additional blood cultures to be obtained without the confounding effect of antibiotics, which is particularly important for patients who have received recent antimicrobial agents and whose initial blood cultures may be negative.</p><p>For patients presenting with hemodynamic instability or acute disease, empiric antibiotics should be initiated promptly <strong>after</strong> three sets of blood cultures have been obtained from separate venipunctures and ideally spaced over 30 to 60 minutes. While culture results are pending in these acutely ill patients, empiric broad-spectrum antibiotic therapy to cover both gram-positive and gram-negative bacteria should be initiated. An empiric regimen including <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and either <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> or a carbapenem with antipseudomonal activity (such as <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>) would provide such coverage. In the context of healthcare-associated infection with concern for multidrug-resistant gram-negative bacilli or enterococcal infection, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> could be added after weighing the associated risk of nephrotoxicity.</p><p class="headingAnchor" id="H1842657420"><span class="h2">Clinical response to initial therapy</span><span class="headingEndMark"> — </span>Most patients with infective endocarditis (IE) become afebrile three to five days after initiation of appropriate antimicrobial therapy. Patients with <em>Staphylococcus aureus</em> endocarditis may respond more slowly, remaining febrile for five to seven days after initiation of therapy. Patients with methicillin resistance in <em>S. aureus</em> (MRSA) infection may experience persistent bacteremia during this period. </p><p>The initial microbiologic response to therapy should be assessed by obtaining repeat blood cultures 48 hours after antibiotics are begun; we advise obtaining two sets of blood cultures every 24 to 48 hours until the bloodstream infection has cleared [<a href="#rid1">1</a>]. </p><p>After initiating antimicrobial therapy, careful serial physical examinations and periodic electrocardiograms (ECGs) should be performed to evaluate for signs of heart failure, emboli, or other complications. This is particularly important if there is persistent bacteremia and/or fever. Patients who develop new complications while on appropriate antimicrobial therapy (such as new emboli, heart failure, conduction disturbances, heart block, or other complications) should have a repeat echocardiogram to assess for worsening valve dysfunction, cardiac abscess, or fistula. (See  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H51057411"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of therapy for PVE is uncertain. In general, we agree with treatment guidelines issued by the American Heart Association and the European Society for Cardiology, which recommend that PVE be treated with an agent(s) that is bactericidal for the isolated microorganism for at least six weeks after the last positive blood culture [<a href="#rid1">1,2</a>].</p><p>This approach is based on observational studies and expert opinion guided by our understanding of the pathogenesis of vegetation formation and pathogen susceptibility. In general, a minimum duration of six weeks is felt to be important given that organisms deep within vegetations or within biofilm are metabolically relatively inactive (and therefore are less responsive to antibiotics) than organisms near the surface. (See  <a class="medical medical_review" href="/z/d/html/2140.html" rel="external">"Pathogenesis of vegetation formation in infective endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Biofilm'</a>.) </p><p>Effective therapy using a shortened duration of parenteral therapy followed by oral therapy was suggested in a study that included patients with PVE [<a href="#rid4">4</a>]; however, this was a single study with a small sample size and with some biases inherent in patient selection. In our opinion, these data do not yet warrant an alteration in the recommended approach to the treatment of PVE. A full course of parenteral therapy is particularly important for patients with virulent or relatively resistant pathogens, secondary cardiac or extracardiac complications, and in the setting of prolonged infection prior to diagnosis. </p><p class="headingAnchor" id="H1210147995"><span class="h2">Completing therapy</span><span class="headingEndMark"> — </span>Patients may complete intravenous therapy as outpatients once it is clear that infection has been controlled and that they are hemodynamically stable. The patient (or a caregiver) must be capable of managing the technical aspects of intravenous therapy. Such patients require careful monitoring and must have ready access to full medical care should complications occur [<a href="#rid1">1,5</a>]. Patients should be counseled regarding the need for immediate evaluation in the setting of new fever, chills, or other signs of systemic toxicity or symptoms suggesting congestive heart failure or neurologic complications. The assessment should include a thorough clinical evaluation, imaging as indicated by symptoms, and repeat blood cultures [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/117307.html" rel="external">"Outpatient parenteral antimicrobial therapy"</a>.)</p><p>While on antimicrobial therapy, patients should be monitored for antimicrobial toxicity. Weekly laboratory monitoring (complete blood count, chemistries, liver and renal function tests, erythrocyte sedimentation rate, and C-reactive protein) should be performed. Serial audiograms may be appropriate for patients receiving long-term aminoglycosides [<a href="#rid1">1</a>]. </p><p>Issues related to echocardiographic monitoring during therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults", section on 'Echo monitoring during therapy'</a>.)</p><p>Patients should be monitored for development of complications related to IE, including embolic events, cardiac conduction disturbances (especially with aortic valve infection in view of the proximity of the valve to the conduction system), and heart failure (see  <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">"Complications and outcome of infective endocarditis"</a>). Development of complications should prompt evaluation for cardiac surgery. (See  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>.)</p><p class="headingAnchor" id="H440575849"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Issues related to follow-up after completion of antibiotic therapy for IE are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">"Overview of management of infective endocarditis in adults", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H2661960420"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>In the absence of paravalvular extension of infection, patients with relapse of PVE following completion of appropriate antimicrobial therapy should receive a repeat course of antibiotics as described in the following sections. Bacterial isolates obtained in the context of relapse should be retested carefully for complete antibiotic susceptibility profiles. </p><p>In addition, patients with relapse of PVE should undergo transesophageal echocardiography (TEE). If TEE does not demonstrate paravalvular extension, further evaluation for extension of infection into paravalvular tissues should be pursued since this frequently requires surgical intervention; diagnostic modalities include 18-flourodeoxglucose F<sup>18</sup>-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT), radiolabeled leukocyte Single-photon emission computed tomography (SPECT)/CT, or cardiac CT angiography (depending upon interval from valve surgery, use of bioadhesive with valve implantation, and available radiographic tools). Patients should also be evaluated for extracardiac sites of infection that may have been inadequately treated.</p><p class="headingAnchor" id="H1719394804"><span class="h1">SPECIFIC PATHOGENS</span><span class="headingEndMark"> — </span>Antimicrobial therapy should be adjusted based on culture results, as described in the following sections. Selection of antimicrobial therapy for PVE is largely based upon clinical experience; in general, the antimicrobial regimen used to treat a specific pathogen causing PVE is based on the treatment used for that organism when it causes native valve endocarditis; staphylococci are an exception. (See <a class="local">'Staphylococci'</a> below and  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis"</a>.)</p><p>If cultures remain negative, therapy for culture-negative PVE should be administered. (See <a class="local">'Culture negative PVE'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Staphylococci</span></p><p class="headingAnchor" id="H1729024225"><span class="h3">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial therapy</strong> – The primary consideration in choosing antimicrobial therapy for treatment of staphylococcal PVE hinges upon whether the organism is sensitive to methicillin and other beta-lactam antibiotics  (<a class="graphic graphic_table graphicRef61202" href="/z/d/graphic/61202.html" rel="external">table 1</a>) [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1">Combination antimicrobial treatment is advised for treatment of staphylococcal PVE. We agree with the American Heart Association (AHA) and the European Society for Cardiology (ESC), which favor a three-drug regimen consisting of a primary antistaphylococcal agent, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (if the organism is susceptible to these agents) [<a href="#rid1">1,2</a>]. The antistaphylococcal agent and rifampin should be administered for at least six weeks; gentamicin should be administered for the initial two weeks of treatment to prevent the emergence of rifampin resistance [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">This antibiotic approach is supported by data from animal models of prosthetic device infection and retrospective clinical series [<a href="#rid6">6,8-11</a>] as well as expert opinion. In one retrospective study including 61 patients with staphylococcal PVE who underwent surgery, valves from patients treated preoperatively with combination therapy were 5.9 times more likely to be culture negative than valves from patients treated with monotherapy; all six patients treated with a triple-drug regimen (including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>) had negative valve cultures at surgery [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1">Inclusion of an aminoglycoside and/or <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> in combination therapy has been questioned by some authors [<a href="#rid12">12,13</a>]; this is discussed further below. (See <a class="local">'Addition of an aminoglycoside'</a> below and <a class="local">'Addition of rifampin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of surgery</strong> – In addition to antimicrobial therapy, staphylococcal PVE may require surgical intervention. In the past, <em>S. aureus</em> PVE was an indication for early surgery; however, the benefits of surgical intervention in this setting are more nuanced than previously recognized, and some patients with <em>S. aureus</em> PVE may be successfully treated with medical therapy alone [<a href="#rid14">14-16</a>]. Issues related to surgery for PVE are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis", section on 'Microorganisms usually requiring surgery'</a>.) </p><p></p><p class="headingAnchor" id="H3467144264"><span class="h3">Primary antistaphylococcal agent</span><span class="headingEndMark"> — </span>For isolates susceptible to methicillin, a semisynthetic penicillinase-resistant penicillin (eg, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a>, or flucloxacillin) is the mainstay of therapy. In patients with penicillin allergy that does not involve anaphylaxis, angioedema, or hives, we are in agreement with the AHA which states that a first-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>) may be substituted for the antistaphylococcal penicillin. </p><p>For isolates resistant to methicillin, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is the agent of choice. For patients with penicillin allergy involving anaphylaxis, angioedema, or hives, vancomycin is also the agent of choice.</p><p>For treatment of PVE due to staphylococcal isolates with reduced <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> susceptibility (minimum inhibitory concentration &gt;1 mcg/mL by broth microdilution or 1.5 mcg/mL by E-test), and for treatment of PVE with inadequate response to vancomycin therapy, the optimal approach is uncertain and clinical experience is limited. In such cases we favor combination therapy with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (8 to 10 mg/kg once daily) plus a beta-lactam (<a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, or <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>), which may result in synergy. The ESC suggests combination therapy with daptomycin and a beta-lactam (oxacillin, flucloxacillin, or ceftaroline) or <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> (not available for parenteral use in the United States) [<a href="#rid2">2</a>]. Other approaches include monotherapy with daptomycin, ceftaroline, <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>, or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> [<a href="#rid17">17-21</a>]. </p><p>If breakthrough bacteremia or microbiologic failure (including isolating the causative staphylococcus from an explanted valve or vegetation) occurs in patients receiving <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, the recovered isolate should be retested for susceptibility to vancomycin, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid22">22</a>]. Daptomycin resistance has emerged during treatment with vancomycin.</p><p>The duration of treatment with the primary antistaphylococcal agent and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is at least six weeks from the time blood cultures become negative. If cultures of an explanted valve or paravalvular abscess are positive, antibiotic therapy should be continued for at least six weeks from the date of surgery. In some patients with persistent bacteremia or slow resolution of fever (suggesting a delayed response to therapy) or in patients treated with a nonstandard regimen, some clinicians continue antibiotic therapy beyond six weeks. </p><p class="headingAnchor" id="H264582804"><span class="h3">Addition of an aminoglycoside</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – An aminoglycoside is used to enhance the antistaphylococcal activity of the primary antistaphylococcal agent, either by synergy or direct activity. In addition, use of multidrug therapy may prevent emergence of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance.</p><p></p><p class="bulletIndent1">If the organism is resistant to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, an alternative aminoglycoside (to which the isolate is susceptible) or <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> should be used to prevent emergence of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance. Based on data from animal models of endocarditis, a fluoroquinolone to which the strain is highly susceptible could be considered in lieu of gentamicin [<a href="#rid23">23-25</a>]. </p><p></p><p class="bulletIndent1">If the organism is resistant to all aminoglycosides, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, and fluoroquinolones, alternative agents that may be used as a third drug (contingent on in vitro susceptibility) include <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid26">26</a>]. If this approach is pursued, we continue the three-drug regimen for the entire course of treatment. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">Delafloxacin</a>, a newer fluoroquinolone approved by the US Food and Drug Administration for treatment of skin and soft tissue infections, retains activity against many methicillin-resistant staphylococci that have become resistant to other fluoroquinolones. The susceptibility of these staphylococci to delafloxacin is reduced relative to susceptible staphylococci, resulting in concern for selection of resistance during therapy, especially in high inoculum infections. There is no clinical experience in the use of delafloxacin in the treatment of PVE; thus, caution and careful follow-up are required if it is used as part of a PVE regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – Use of multidrug therapy may prevent emergence of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance; this is supported by in vitro studies as well as clinical reports of emergence of rifampin resistance in the setting of high-inoculum infection treated with a single antistaphylococcal agent plus rifampin. </p><p></p><p class="bulletIndent1">In a small, randomized trial including patients with methicillin-resistant coagulase-negative staphylococcal PVE, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance emerged in 7 of 19 patients (37 percent) treated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus rifampin but in none of 13 patients treated with vancomycin, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, and rifampin (not significant) [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H1515347651"><span class="h3">Addition of rifampin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – The approach to treatment of staphylococcal PVE consists of initial antibiotic therapy with two antimicrobial agents other than <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (eg, a primary antistaphylococcal agent and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, if feasible based on antimicrobial susceptibility and renal function) for three to five days <strong>prior</strong> to initiation of rifampin. If the susceptibility of the isolate precludes treatment with two antistaphylococcal antimicrobials, treatment with a single agent should be administered for five days before beginning rifampin. </p><p></p><p class="bulletIndent1">It is important to delay the initiation of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> until the bacterial density at the site of infection is significantly reduced. The bacterial gene controlling the site of action for rifampin has a relatively high intrinsic mutation rate; therefore, if large numbers of organisms are exposed to rifampin (either alone or in combination with ineffective antimicrobial agents), a rifampin-resistant subpopulation may emerge rapidly [<a href="#rid6">6,23</a>]. Ideally, delayed initiation of rifampin allows opportunity for reduction in the staphylococcal burden, thereby reducing the likelihood that a rifampin-resistant subpopulation will emerge. </p><p></p><p class="bulletIndent1">If breakthrough bacteremia or microbiologic failure occurs in patients on a rifampin-containing regimen, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> susceptibility should be reassessed [<a href="#rid6">6</a>]. If the isolate has become resistant to rifampin, rifampin should be discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> appears to be unique in its ability to kill stationary growth-phase staphylococci embedded in biofilm that is adherent to infected foreign material; this is based on in vitro data, evidence from animal model experiments, and clinical observations [<a href="#rid6">6,10,11,23-25,27</a>]. </p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is supported by the following studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a post-hoc analysis of a prospective cohort study including 964 patients with <em>S. aureus</em> bacteremia (including 374 patients with deep-seated infection, of whom 121 had endocarditis), outcomes were compared among those receiving combination antibiotic therapy (most frequently including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>) and those not receiving combination therapy. On analysis using a Cox model with a time-dependent covariable, there was no difference between the two groups in 30- or 90-day mortality [<a href="#rid28">28</a>]. However, in the subgroup with implanted foreign bodies treated with a combination regimen that included rifampin, reduced 30-day (hazard ratio [HR] 0.53, 95% CI 0.26-1.07) and 90-day (HR 0.55, 95% CI 0.33-0.91) mortality were observed. In addition, late complications of <em>S. aureus</em> bacteremia, including relapse, were reduced among recipients of combination therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial including more than 750 patients with <em>S. aureus</em> bacteremia treated with an antistaphylococcal regimen and randomly assigned to addition of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> or placebo, a small reduction in clinical and microbiologic recurrence of infection was observed in patients who received a rifampin-containing regimen [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">However, a retrospective study [<a href="#rid12">12</a>] and a systematic literature review [<a href="#rid13">13</a>] have questioned the benefit of combination antibiotic regimens for treatment of staphylococcal PVE:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The retrospective study included 180 PVE cases, of which 114 were caused by <em>S.</em> <em>aureus</em> and 66 by coagulase negative staphylococci; methicillin resistance was noted in 17 and 39 patients in these groups, respectively [<a href="#rid12">12</a>]. Overall, in-hospital and one-year mortality rates were 23 and 35 percent, respectively. In comparing the outcome of 101 patients treated with a rifampin-containing regimen (median <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> duration 33 days [interquartile range 12.5 to 41.2]) to 79 patients not receiving rifampin, the in-hospital and one-year mortality and relapse rates in the two groups were not significantly different. Details of the primary antistaphylococcal therapy were not provided for either study arm. The treatment groups appeared comparable; however, the study was retrospective and thus limited by undetected selection bias. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The literature review stated that the ESC and AHA recommendation for a combination antimicrobial regimen including <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> was not based on sufficient clinical data, but largely on expert opinion combined with animal model studies [<a href="#rid13">13</a>]. In view of the potential toxicities associated with combination therapy, the authors suggested that <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and rifampin for treatment of PVE be used primarily within the context of clinical trials. </p><p></p><p class="bulletIndent1">Nonetheless, given the high mortality rates for staphylococcal PVE (25 percent in-hospital and 35 percent at one year), we continue to prefer the combination regimens recommended by the AHA and ESC. The potential benefits support its use, particularly in patients treated medically (in whom infected biofilm may pose a unique challenge). The potential for adverse events and drug-drug interactions must be managed with careful monitoring [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H6"><span class="h2">Streptococci</span></p><p class="headingAnchor" id="H2019652553"><span class="h3">Viridans streptococci and S. bovis/S. equinus complex</span><span class="headingEndMark"> — </span>For treatment of streptococcal PVE in the United States, the penicillin susceptibility of viridans group streptococci and <em>Streptococcus bovis/Streptococcus equinus </em>complex  (<a class="graphic graphic_table graphicRef89670" href="/z/d/graphic/89670.html" rel="external">table 2</a>) are defined in the AHA treatment guidelines [<a href="#rid1">1</a>]; the British Society for Antimicrobial Chemotherapy guidelines and the ESC guidelines use different minimum inhibitory concentration (MIC) susceptibility parameters  (<a class="graphic graphic_table graphicRef61640" href="/z/d/graphic/61640.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef71412" href="/z/d/graphic/71412.html" rel="external">table 4</a>) [<a href="#rid2">2,30</a>]. In the United States, most streptococci that cause endocarditis are highly penicillin susceptible (MIC ≤0.12 mcg/mL); occasional strains are relatively resistant to penicillin (MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL), and rare strains are fully resistant to penicillin (MIC ≥0.5 mcg/mL) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H174157049"><span class="h4">Penicillin-susceptible strains</span><span class="headingEndMark"> — </span>For treatment of streptococcal PVE due to penicillin-susceptible strains, we are in agreement with the AHA, which recommends a beta-lactam antibiotic (eg, penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) for six weeks, with the option to add an aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>) for the initial two weeks. The addition of an aminoglycoside is relatively contraindicated in the setting of renal insufficiency and cranial nerve VIII dysfunction [<a href="#rid6">6</a>]. An alternative regimen for beta-lactam intolerant patients consists of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> monotherapy for six weeks. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef61640" href="/z/d/graphic/61640.html" rel="external">table 3</a>). </p><p>Combination beta-lactam-aminoglycoside therapy is used to achieve synergistic killing of streptococci [<a href="#rid32">32</a>]. This approach is based on in vitro studies, in vivo studies using experimental endocarditis models, clinical series, and clinical experience [<a href="#rid7">7,33</a>]. However, there are no studies demonstrating the superiority of combination therapy over penicillin monotherapy. In addition, studies have demonstrated that various genetic pathways mediate high-level resistance to <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> (and less frequently to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>) in a small percentage of streptococci that cause endocarditis; in these isolates, the presence of high-level aminoglycoside resistance abrogates the bactericidal synergy of combination therapy [<a href="#rid34">34-37</a>]. </p><p>To avoid the potential exposure to aminoglycoside toxicity in the absence of therapeutic benefit, laboratory testing for high-level <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistance should be performed prior to initiation of combination therapy, if possible. However, the optimal approach to screening streptococci for high-level aminoglycoside resistance is uncertain, and there is no Clinical and Laboratory Standards Institute guidance. Bacterial growth on brain-heart infusion agar plates (which are commercially available for screening enterococci) in the face of high aminoglycoside concentrations is suggestive of high-level resistance and loss of bactericidal synergy with combination therapy.</p><p class="headingAnchor" id="H443964512"><span class="h4">Relatively penicillin-resistant strains</span><span class="headingEndMark"> — </span>The preferred regimen for streptococcal PVE due to relatively penicillin-resistant strains (MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL) consists of combination therapy with a beta-lactam antibiotic (eg, penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) for six weeks and an aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>). Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef71412" href="/z/d/graphic/71412.html" rel="external">table 4</a>). </p><p>The optimal approach to administration of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (dosing and duration) is uncertain; our approach differs from that suggested by the AHA and ESC. We administer gentamicin 3 mg/kg/day in three divided doses (rather than a single daily dose, as favored by the AHA and ESC) for a minimum of two weeks (rather than six weeks, as favored by the AHA and ESC). We favor divided dosing to maintain a bactericidal level throughout the day, given that the cell wall agent may be bacteriostatic (rather than bactericidal) for relatively resistant streptococci. We favor a two-week duration based on limited data from treatment of native valve endocarditis with these organisms and the increased risk of aminoglycoside nephrotoxicity and cranial nerve VIII toxicity with longer courses of therapy. </p><p>Prior to initiation of combination therapy, laboratory testing for high-level <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistance should be performed, if possible. (See <a class="local">'Penicillin-susceptible strains'</a> above.)</p><p>If aminoglycoside therapy is relatively contraindicated (eg, in the setting of renal insufficiency or cranial nerve VIII dysfunction), or the strain is <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistant, monotherapy with a beta-lactam antibiotic may be given [<a href="#rid6">6</a>]. An alternative regimen consists of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> monotherapy for six weeks. </p><p class="headingAnchor" id="H2059431580"><span class="h4">Fully penicillin-resistant strains</span><span class="headingEndMark"> — </span>For patients with PVE due to fully penicillin-resistant streptococci (defined by the AHA as MIC ≥0.5 mcg/mL), management consists of combination therapy with a beta-lactam antibiotic (eg, penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) for six weeks and, in the absence of high-level resistance, an aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>). In such cases we administer gentamicin (3 mg/kg/day in three divided doses) for six weeks. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef71412" href="/z/d/graphic/71412.html" rel="external">table 4</a>).</p><p>A similar approach is used to treat PVE caused by streptococci-like organisms: <em>Abiotrophia defectiva</em>, <em>Granulicatella</em> spp, and <em>Gemella</em> spp. While a regimen of high-dose penicillin or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> may be used initially, confirming the antimicrobial susceptibility of the isolate is important in the selection of optimal treatment. Notably, among <em>Granulicatella</em> <em>adiacens</em>, penicillin susceptibility does not predict <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> susceptibility (in contrast to <em>Abiotrophia defectiva</em>); this must be tested specifically.</p><p>If the patient is intolerant of penicillin and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or if <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> cannot be used, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> monotherapy should be used; we do not give gentamicin with vancomycin because of the increased risk of nephrotoxicity with coadministration of these agents.</p><p class="headingAnchor" id="H461321988"><span class="h4">Penicillin allergy</span><span class="headingEndMark"> — </span>For patients with immediate-type reactions (urticaria or anaphylaxis) to penicillin, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is an acceptable alternative regimen. For patients with non-immediate type reactions, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> may be used. (See  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.) </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> should not be used routinely as an alternative to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of endocarditis caused by non-speciated viridans streptococci; emergence of stable high-level resistance to daptomycin has been noted in at least 25 percent of the <em>Streptococcus mitis</em> group isolates (<em>S. mitis, Streptococcus oralis, and Streptococcus sanguinis</em>) with exposure to daptomycin in vitro and in experimental endocarditis models. Resistance has also emerged in <em>Streptococcus parasanguinis, Abiotrophia </em>spp<em>,</em> and<em> Granulicatella adiacens</em> [<a href="#rid38">38-40</a>].<em> </em>In vitro<em> </em>and endocarditis model studies suggest that the likelihood of emergence of daptomycin resistance in streptococci may be diminished when daptomycin is combined with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, although this approach would not be recommended therapy [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H3973463441"><span class="h3">Other streptococci</span><span class="headingEndMark"> — </span>For treatment of PVE due to penicillin-susceptible <em>Streptococcus pneumoniae</em> (in the absence of meningitis) or a <em>Streptococcus</em> belonging to serogroups A, B, C, F, and G, the regimen consists of penicillin or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, as for penicillin-susceptible viridans streptococci for six weeks  (<a class="graphic graphic_table graphicRef61640" href="/z/d/graphic/61640.html" rel="external">table 3</a>). For serogroups B, C, F, and G, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> may be administered for the initial two weeks; gentamicin is not used for serogroup A because these strains are highly susceptible to penicillin. </p><p>For treatment of PVE due to <em>S. pneumoniae</em> with relative or full penicillin resistance (MIC ≥0.12 mcg/mL) in the absence of meningitis, the regimens in the table may be used  (<a class="graphic graphic_table graphicRef61640" href="/z/d/graphic/61640.html" rel="external">table 3</a>). In such cases, adding an aminoglycoside is not recommended. </p><p>For treatment of PVE due to penicillin-resistant pneumococci complicated by meningitis, the regimen must be adjusted to ensure adequate antimicrobial penetration into the cerebrospinal fluid (with meningeal doses of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, or both, contingent on susceptibility). (See  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Enterococci</span><span class="headingEndMark"> — </span>Bactericidal activity against enterococci can be achieved with the synergistic interaction of a cell wall active agent (penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) and an aminoglycoside (<a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>). The cell wall agent is bacteriostatic against enterococci but promotes entry of the aminoglycoside into the cell, where it is bactericidal [<a href="#rid43">43</a>].</p><p>To achieve this interaction, the organism (<em>E. faecalis</em> or <em>E. faecium</em>) must be susceptible to the cell wall active agent at achievable serum concentrations and must be susceptible to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (at 500 mcg/mL) or <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> (at 1000 mcg/mL in broth or at 2000 mcg/mL on agar culture). High-level resistance to gentamicin and streptomycin is mediated by two independent genes; therefore, organisms could be tested for high-level resistance to each of these drugs. Growth in the presence of the aminoglycoside at the above concentrations indicates high-level resistance and precludes a synergistic bactericidal effect when that aminoglycoside is combined with a cell wall active agent. In addition, gentamicin resistance at the above concentration indicates that synergy cannot be achieved with netilmicin, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, or kanamycin. </p><p>Bactericidal synergy against <em>Enterococcus faecalis</em> (but not <em>Enterococcus faecium</em>) also can be achieved by combining two beta-lactam antibiotics. Exposure of <em>E. faecalis</em> to high concentrations of <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> plus <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> results in bactericidal synergy through the saturation of penicillin binding proteins 2, 3, 4, and 5; this synergy is achieved irrespective of high-level resistance to aminoglycosides. In animal models of <em>E. faecalis</em> endocarditis, treatment with ampicillin plus ceftriaxone was comparable to ampicillin plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and was also effective against <em>E. faecalis</em> with high-level gentamicin resistance [<a href="#rid43">43-46</a>]. These observations have led to use of a double beta-lactam regimen (ampicillin plus ceftriaxone) for treatment of <em>E. faecalis</em> endocarditis. However, dual beta-lactam therapy may not provide synergistic bactericidal activity against <em>E. faecium</em> and has not been shown effective for treatment of endocarditis due to this species [<a href="#rid47">47,48</a>].</p><p>Antibiotic resistance among enterococci has become significantly more common, necessitating careful testing of each strain causing endocarditis to select a synergistic regimen [<a href="#rid49">49,50</a>]. Ideally all enterococci causing IE should be speciated; for resistant strains, speciation is essential. </p><p class="headingAnchor" id="H3852502205"><span class="h3">Susceptible strains</span></p><p class="headingAnchor" id="H1830558800"><span class="h4">General approach</span><span class="headingEndMark"> — </span>The AHA and the ESC guidelines recommend two types of regimens for treatment of PVE caused by susceptible enterococci:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-lactam combination regimen </strong>–<strong> </strong>This regimen for treatment of PVE caused by <em>Enterococcus faecalis</em> (but not <em>E. faecium)</em> combines treatment with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>. In three retrospective studies, the efficacy of this regimen has been comparable in efficacy to the above regimen and has been associated with significantly less frequent nephrotoxicity [<a href="#rid44">44-46,51</a>]. Accordingly, this regimen is being used increasingly, particularly in patients with pre-existing renal dysfunction or in whom the risk of nephrotoxicity or oto/vestibular toxicity is a concern [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1">Data supporting use of a beta-lactam combination regimen are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'General approach'</a> and  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections", section on 'Bacteremia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycoside combination regimen</strong> – This regimen combines a cell wall active agent (penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> [<a href="#rid1">1,2</a>]. Gentamicin is administered with divided dosing (three times daily) to maintain a bactericidal level throughout the day for bactericidal synergy  (<a class="graphic graphic_table graphicRef50418" href="/z/d/graphic/50418.html" rel="external">table 5</a>). This approach is based on in vitro studies, animal models, and clinical series [<a href="#rid43">43,51</a>].</p><p></p><p class="headingAnchor" id="H3259152193"><span class="h4">Emergence of nephrotoxicity during therapy</span><span class="headingEndMark"> — </span>If nephrotoxicity or oto/vestibular toxicity emerge while using a gentamicin-containing regimen, we discontinue <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and switch to the dual beta-lactam regimen. (See <a class="local">'General approach'</a> above.)</p><p>An alternative approach to mitigate potential nephrotoxicity during treatment with the aminoglycoside combination regimen is to reduce the duration of aminoglycoside treatment [<a href="#rid52">52,53</a>]. This approach is supported by a prospective study including 27 cases of enterococcal PVE; clinical cure was achieved in 78 percent of cases [<a href="#rid52">52</a>]. Among cured patients, a cell wall active agent was given for a median of 42 days, and a synergistic aminoglycoside was given for a median of 15 days. </p><p class="headingAnchor" id="H3561115390"><span class="h4">Penicillin allergy</span><span class="headingEndMark"> — </span>Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> for six weeks  (<a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">table 6</a>). If the risk of nephrotoxicity with this regimen is unacceptable, patients should be desensitized to penicillin to allow treatment with penicillin or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> plus an aminoglycoside or ampicillin plus <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>. Patients with a less definitive history of beta-lactam allergy should be evaluated by an allergy consultant in an effort to clarify the history and facilitate use of the preferred beta-lactam based therapies if feasible.</p><p class="headingAnchor" id="H58059028"><span class="h3">Gentamicin resistance</span><span class="headingEndMark"> — </span>For PVE caused by <em>E. faecalis</em> strains susceptible to penicillin, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> but with high-level resistance to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, we favor treatment with a beta-lactam combination regimen (<a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> plus <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> for six weeks). For strains that do not exhibit high-level resistance to streptomycin, the combination of penicillin or ampicillin plus streptomycin will provide bactericidal synergy and may be used, provided that the patient does not have pre-existing renal dysfunction or cranial nerve VIII dysfunction. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef104581" href="/z/d/graphic/104581.html" rel="external">table 7</a>).</p><p>If the enterococcus exhibits high-level resistance to <strong>both</strong> <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, no available aminoglycoside will provide bactericidal synergy; thus, an aminoglycoside should <strong>not</strong> be administered. If the isolate is <em>E.</em> <em>faecalis,</em> the beta-lactam combination regimen should remain effective (see <a class="local">'General approach'</a> above) [<a href="#rid44">44-46</a>]. Prolonged treatment with a cell wall active agent alone (eg, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> for 8 to 12 weeks) may be effective, but the risk of relapse is high [<a href="#rid54">54</a>]. </p><p><em>E. faecium</em> is a relatively infrequent cause of PVE; but when this species does cause infection, it is typically resistant to multiple antibiotics, and optimal treatment is not certain. (See <a class="local">'Resistance to penicillins, aminoglycosides, and vancomycin'</a> below.)</p><p class="headingAnchor" id="H2269348195"><span class="h3">Penicillin resistance</span><span class="headingEndMark"> — </span>Intrinsic high-level penicillin resistance in enterococci is usually due to alterations in penicillin-binding proteins. For patients with PVE due to enterococcal strains with intrinsic high-level penicillin resistance, we are in agreement with the AHA which recommends combination therapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> for six weeks. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">table 6</a>).</p><p>Occasionally, <em>E. faecalis</em> may be resistant to penicillin and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> by virtue of beta-lactamase production; if this is suspected, confirmation by testing for beta-lactamase can be requested. In such cases, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> could be used as the cell wall active agent in a combination regimen with an aminoglycoside, contingent on absence of high-level resistance.</p><p class="headingAnchor" id="H2019654822"><span class="h3">Resistance to penicillins, aminoglycosides, and vancomycin</span><span class="headingEndMark"> — </span>For PVE caused by vancomycin-resistant <em>E. faecium</em> (VRE) organisms (which often are also resistant to penicillin and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> and highly resistant to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>), the optimal approach is uncertain  (<a class="graphic graphic_table graphicRef66444" href="/z/d/graphic/66444.html" rel="external">table 8</a>). A full evaluation of the isolate's resistance profile is required for selection of therapy. Occasionally, a standard regimen is available. Infectious disease consultation is advised. </p><p>In general, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is active against enterococci, including VRE [<a href="#rid31">31</a>]. Clinical experience with daptomycin treatment of enterococcal endocarditis is limited, raising important concerns regarding reporting bias [<a href="#rid55">55</a>]. In general, if daptomycin is used, it should be administered in high doses (10 to 12 mg/kg IV once daily) and combined with either <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> or <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>. While combination with either of these beta-lactam agents may enhance the bactericidal activity of daptomycin (even against daptomycin-resistant enterococci), this effect is related to gene mutations that regulate the cell membrane and is difficult to predict [<a href="#rid56">56-58</a>]. </p><p><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> is often active against <em>E. faecium</em> and <em>E. faecalis</em>, but its effectiveness in the treatment of PVE caused by VRE is not fully established [<a href="#rid1">1,59</a>]. <a class="drug drug_general" data-topicid="9515" href="/z/d/drug information/9515.html" rel="external">Quinupristin-dalfopristin</a> is active against <em>E. faecium</em> but causes unacceptable infusion-related toxicity that usually precludes routine use. </p><p>Patients with PVE caused by extensively antibiotic-resistant enterococci should be managed with the assistance of infectious disease consultation [<a href="#rid43">43</a>]; </p><p>For patients with PVE due to highly resistant enterococci, consultation regarding surgical intervention during suppressive bacteriostatic therapy is warranted; in addition, surgery may be warranted for patients not responsive to antimicrobial therapy. (See  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">HACEK organisms</span><span class="headingEndMark"> — </span>The fastidious gram-negative bacilli, <em>Haemophilus</em>, <em>Aggregatibacter</em>, <em>Cardiobacterium</em>, <em>Eikenella</em>, <em>Kingella</em> (HACEK organisms), are highly susceptible to third-generation cephalosporins; some are ampicillin-resistant due to the production of beta-lactamase. For treatment of HACEK PVE, we are in agreement with the AHA, which recommends treatment with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (or a comparable third- or fourth-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, respectively) for six weeks. <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">Ampicillin</a> (or <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>/<a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>) should be used only if growth in vitro is sufficiently vigorous to allow reliable susceptibility testing and confirms susceptibility. For patients unable to tolerate a cephalosporin or ampicillin, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or another fluoroquinolone may be used  (<a class="graphic graphic_table graphicRef70411" href="/z/d/graphic/70411.html" rel="external">table 9</a>) [<a href="#rid1">1</a>]. </p><p>The ESC recommends <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> for six weeks. If the isolate does not produce beta-lactamase and is <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> susceptible, ampicillin in combination with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is an option. The ESC cites <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> as another possible therapy, although it is less extensively studied for this indication [<a href="#rid2">2</a>]. Use of ampicillin-gentamicin combination therapy is not well established, and aminoglycoside exposure may expose patients to nephrotoxicity risks. </p><p>Patients with HACEK PVE who do not have valvular dysfunction can often be cured with antibiotics alone [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Other gram-negative organisms</span><span class="headingEndMark"> — </span>Treatment of PVE caused by non-HACEK gram-negative bacilli should be based upon the susceptibility of the causative organism. Combination antimicrobial therapy with a beta-lactam (penicillins, cephalosporins, or carbapenems) and either an aminoglycoside or fluoroquinolone for six weeks is reasonable [<a href="#rid1">1,2</a>]. Maximal doses of the selected antimicrobials (eg, rather than the low doses used for synergy) should be used in an attempt to expose a potentially high bacterial inoculum deep in vegetations to high antimicrobial concentrations. The rationale for combination therapy is to minimize the likelihood of antibiotic resistance in the setting of a potentially large bacterial burden within the protected environment of vegetation. These patients should be treated in conjunction with an infectious disease consultant.</p><p>Surgery to excise the infected valve is often required in PVE due to gram-negative bacilli, especially that caused by <em>Pseudomonas aeruginosa</em> or when infection involves the left-sided heart valves. </p><p class="headingAnchor" id="H2293781738"><span class="h2">Corynebacteria (diphtheroids)</span><span class="headingEndMark"> — </span>For PVE due to organisms susceptible to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (MIC &lt;4.0 mcg/mL), treatment consists of penicillin plus gentamicin, which will result in synergistic bactericidal activity. </p><p><a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">Gentamicin</a> resistance precludes bactericidal synergy [<a href="#rid61">61</a>]. For gentamicin-resistant strains, treatment for six weeks with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, which is bactericidal against diphtheroids, is warranted. Vancomycin is also appropriate in the setting of penicillin allergy or concern for aminoglycoside nephrotoxicity. </p><p class="headingAnchor" id="H11"><span class="h2">Fungi</span><span class="headingEndMark"> — </span>Treatment of fungal endocarditis consists of antifungal therapy and generally valve replacement.</p><p>Issues related to Candida endocarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a>.)</p><p>Issues related to endocarditis caused by <em>Aspergillus</em> are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Antifungal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Duration'</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Role of surgery'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">CULTURE NEGATIVE PVE</span><span class="headingEndMark"> — </span>Culture-negative infective endocarditis (IE) is defined as endocarditis without etiology following inoculation of three blood samples in a standard blood culture system (eg, negative cultures after seven days) [<a href="#rid1">1</a>].</p><p>Cultures are negative in IE for three major reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of antimicrobial agents prior to obtaining blood cultures </p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate microbiologic techniques</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with fastidious bacteria or nonbacterial pathogens </p><p></p><p>In the absence of prior antibiotic exposure, the most common causes of culture-negative IE are fastidious organisms (eg, fastidious bacteria, zoonotic agents and fungi); in the setting of prior antibiotic exposure, the most common causes are <em>Streptococcus</em> spp. Additional diagnostic evaluations (such as next-generation sequencing of plasma for pathogen DNA, polymerase chain reaction testing of vegetation, vegetation microscopy, or serology) can be used to pursue identification of the etiologic agent. (See  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis", section on 'Culture-negative endocarditis'</a>.) </p><p>Other pathogens for consideration include: </p><p class="bulletIndent1"><span class="glyph">●</span><em>Coxiella burnetii </em>is a relatively common cause of culture-negative endocarditis; the frequency varies in different geographic locations. Further information regarding Q fever can be found on the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fqfever%252Fhealthcare-providers%252Findex.html%26data%3D05%7C01%7CJenny.McKay%2540wolterskluwer.com%7Cf5454b09c6e54b56b9ea08dad95dd1c4%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C638061294256462617%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C3000%7C%7C%7C%26sdata%3Dehb4D27y8F8T706KmduRn3VpDSIsGHCjR4HQBXcIiFM%253D%26reserved%3D0&amp;token=Xt%2B85laJ6bcQ6q5XXpQV7vy%2B2UOEfGwRS6NHH0NsBAIpzqxNezHO0cMauL%2FCBcU9o5pvWUpMYjqE%2FB6Y%2FOFw5JMGBfO7A%2FE4b2pB3%2FQz0Z4%2BszvVu7bVfnwJ%2Bu4zo5Dq0G8dtdi7nBF9VeN2syZfjSnK2RQRUrzENFg9iq59Qr4oxwaRcY5BBoa791hOv0wTnH%2BENjbUlifAHIBUZQ5zI1B%2BO2YdzNylUK4hTGvoCZaVSgkgecXhi5om6ke78P3zegeCm0q5dSq1UgOD99vRlm10eJ7sIdRRPVOA8WAB4SOxq4xhyvsHYIRAItaTtop0YEYdHWAiBiGQSxYMrxP8OLDH%2FF5e2F76D66czPHPXtfs3OQlLNDzrl1OVXY88A%2FHask%2Bgb56Bd2xLfgvSn%2FPfuy020XGQwTUS%2FlFvG8hRihnLjXdQKszJCuUOcVMWuISZAnH%2BdgZLSXLqDUZ7MV0pA%3D%3D&amp;TOPIC_ID=2141" target="_blank">Centers for Disease Control and Prevention website</a> [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal endocarditis should be considered, especially in patients with a complex perioperative course. (See <a class="local">'Fungi'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, culture-negative PVE due to atypical mycobacteria has been described. Reports have described valve contamination during manufacture. <em>Mycobacterium chimaera</em> has caused culture-negative PVE, although this organism can be recovered from blood when cultures are placed in special media. This infection has occurred as a consequence of intraoperative wound contamination by aerosol from contaminated heater-cooler machines used during cardiopulmonary bypass. These cases can have an indolent, markedly delayed onset (eg, years after valve replacement surgery) and can present with multiple foci of infection [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections", section on 'M. chimaera associated with cardiac surgery'</a>.)</p><p></p><p>Empiric treatment of patients with culture-negative PVE should be pursued in consultation with an infectious disease specialist. We are in agreement with the AHA, which favors the following initial approach while awaiting results from an expanded diagnostic evaluation [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Onset ≤1 year after surgery</strong> – Patients with culture-negative PVE with onset ≤1 year after surgery should receive antimicrobial therapy for coverage of infection due to staphylococci, enterococci, and aerobic gram-negative bacilli. Broad coverage can be achieved using an empiric regimen with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> as well as <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> or a carbapenem with activity against <em>P. aeruginosa</em>. With an acute septic onset, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> can be added to further enhance coverage, with care to avoid nephrotoxicity. Addition of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> can be delayed at least three to five days after start of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Onset &gt;1 year after surgery</strong> – Patients with culture-negative PVE onset &gt;1 year after surgery should receive antimicrobial therapy for coverage of infection due to staphylococci, viridans group streptococci, enterococci, and HACEK organisms. Empiric therapy could be initiated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>; this regimen provides initial empiric coverage but is not adequate treatment for enterococcal infection. </p><p></p><p class="bulletIndent1">Patients with nosocomial or hospital-associated culture-negative PVE should be treated empirically as outlined above for patients with onset ≤1 year after valve implantation.</p><p></p><p>If additional diagnostic evaluations identify the etiologic agent, antibiotic therapy should be targeted accordingly. If negative blood cultures may be attributable to prior antimicrobial exposure, consideration should be given to the prior antimicrobial's spectrum of activity and the patient's relevant epidemiology to select empiric therapy.</p><p class="headingAnchor" id="H2424987232"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112042.html" rel="external">"Society guideline links: Treatment and prevention of infective endocarditis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/121914.html" rel="external">"Society guideline links: Outpatient parenteral antimicrobial therapy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General considerations </strong>− Management of prosthetic valve endocarditis (PVE) requires bactericidal antimicrobial therapy, monitoring for complications, and assessment of indications for surgical intervention. Specific recommendations provided are based upon clinical experience and in vitro studies, rather than on clinical trial data showing a benefit for clinical outcomes. (See <a class="local">'General considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric therapy</strong> − Empiric therapy prior to a microbiologic diagnosis is not always necessary. (See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with hemodynamic instability and clinical presentation suggestive of acute endocarditis (fever and new murmur, particularly in the setting of relevant cardiac risk factors or other predisposing conditions), we suggest administration of empiric antibiotic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">Empiric antibiotic therapy may be initiated after three sets of blood cultures have been obtained. We suggest an empiric regimen that covers gram-positive and gram-negative bacteria, such as <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (for synergy), and either <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> or a carbapenem with antipseudomonal activity (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with suspected PVE who are hemodynamically stable with an indolent clinical course, therapy can be delayed briefly while awaiting blood culture results. In patients with prior antibiotic exposure, the delay allows obtaining repeat cultures with reduced confounding by prior therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted therapy</strong> − Therapy for PVE should be targeted to the organism isolated from blood cultures, along with the in vitro susceptibility results. The approach is summarized in the tables and is discussed in the sections above:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Staphylococci  (<a class="graphic graphic_table graphicRef61202" href="/z/d/graphic/61202.html" rel="external">table 1</a>) − For treatment of staphylococcal PVE, we suggest combination therapy with a three-drug regimen which includes a primary antistaphylococcal agent, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, rather than one- or two-drug regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The antistaphylococcal agent and rifampin should be administered for at least six weeks; gentamicin should be administered for the initial two weeks of treatment. Alternative regimens are suggested for resistant organisms. (See <a class="local">'Staphylococci'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suggested regimens are provided for the following pathogens in the relevant sections and tables above:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Viridans streptococci and <em>Streptococcus bovis/Streptococcus equinus comp</em>lex  (<a class="graphic graphic_table graphicRef61640" href="/z/d/graphic/61640.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef71412" href="/z/d/graphic/71412.html" rel="external">table 4</a>)  </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><em>Streptococcus pneumoniae</em> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Streptococcal groups A, B, C, F, and G </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Enterococci  (<a class="graphic graphic_table graphicRef50418" href="/z/d/graphic/50418.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef104581" href="/z/d/graphic/104581.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef66444" href="/z/d/graphic/66444.html" rel="external">table 8</a>) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>HACEK (<em>Haemophilus</em>, <em>Aggregatibacter</em>, <em>Cardiobacterium</em>, <em>Eikenella</em>, <em>Kingella)</em> organisms  (<a class="graphic graphic_table graphicRef70411" href="/z/d/graphic/70411.html" rel="external">table 9</a>) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other non-HACEK gram-negative organisms </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Corynebacteria (diphtheroids) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fungi </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Culture-negative endocarditis </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment duration </strong>−<strong> </strong>We suggest that patients with PVE be treated with parenteral antibiotics for at least six weeks rather than for shorter durations (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Some data suggest that a shortened duration of intravenous therapy may be sufficient in some cases; however, thus far, the weight of this evidence has been insufficient to change practice. This approach is based upon our understanding of the pathogenesis of vegetation formation and pathogen susceptibility, rather than on an evidence-based approach based on outcome data. (See <a class="local">'Duration of therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring during treatment</strong> − Patients with PVE require careful regular clinical follow-up including serial physical examinations and obtaining follow-up blood cultures to document clearance of bacteremia. Patients should be monitored for development of complications including embolic events and heart failure. Development of complications should prompt evaluation for cardiac surgery. (See <a class="local">'Clinical response to initial therapy'</a> above and <a class="local">'Completing therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.</a></li><li><a class="nounderline abstract_t">Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</a></li><li><a class="nounderline abstract_t">Del Val D, Abdel-Wahab M, Linke A, et al. Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement. Clin Infect Dis 2021; 73:e3750.</a></li><li><a class="nounderline abstract_t">Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019; 380:415.</a></li><li><a class="nounderline abstract_t">Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68:e1.</a></li><li class="breakAll">Karchmer AW. Infections of Prosthetic Heart Valves. In: Infections Associated with Indwelling Medical Devices, 3rd ed, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology, Washington, DC 2000. p.145.</li><li><a class="nounderline abstract_t">Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274:1706.</a></li><li><a class="nounderline abstract_t">Drinković D, Morris AJ, Pottumarthy S, et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 2003; 52:820.</a></li><li><a class="nounderline abstract_t">Karchmer AW, Archer GL, Dismukes WE. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 Suppl 3:S543.</a></li><li><a class="nounderline abstract_t">Archer GL, Johnston JL, Vazquez GJ, Haywood HB 3rd. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis 1983; 5 Suppl 3:S538.</a></li><li><a class="nounderline abstract_t">Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 Suppl 3:S533.</a></li><li><a class="nounderline abstract_t">Le Bot A, Lecomte R, Gazeau P, et al. Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study. Clin Infect Dis 2021; 72:e249.</a></li><li><a class="nounderline abstract_t">Ryder JH, Tong SYC, Gallagher JC, et al. Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis. Open Forum Infect Dis 2022; 9:ofac583.</a></li><li><a class="nounderline abstract_t">Lalani T, Chu VH, Park LP, et al. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med 2013; 173:1495.</a></li><li><a class="nounderline abstract_t">Chirouze C, Alla F, Fowler VG Jr, et al. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study. Clin Infect Dis 2015; 60:741.</a></li><li><a class="nounderline abstract_t">Karchmer AW, Bayer AS. Editorial commentary: surgical therapy for Staphylococcus aureus prosthetic valve endocarditis: proceed with caution (Caveat Emptor). Clin Infect Dis 2015; 60:750.</a></li><li><a class="nounderline abstract_t">Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005; 34:69.</a></li><li><a class="nounderline abstract_t">Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.</a></li><li><a class="nounderline abstract_t">Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51.</a></li><li><a class="nounderline abstract_t">Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther 2014; 36:1303.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317.</a></li><li><a class="nounderline abstract_t">Cubicin resistance should be closely monitored in bacteremia patients. The Pink Sheet 2006; 68:11.</a></li><li><a class="nounderline abstract_t">Chuard C, Herrmann M, Vaudaux P, et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35:2611.</a></li><li><a class="nounderline abstract_t">Lucet JC, Herrmann M, Rohner P, et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34:2312.</a></li><li><a class="nounderline abstract_t">Rouse MS, Wilcox RM, Henry NK, et al. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 1990; 34:273.</a></li><li><a class="nounderline abstract_t">Souli M, Pontikis K, Chryssouli Z, et al. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. Eur J Clin Microbiol Infect Dis 2005; 24:760.</a></li><li><a class="nounderline abstract_t">Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98:447.</a></li><li><a class="nounderline abstract_t">Rieg S, Joost I, Weiß V, et al. Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia-a post hoc analysis in 964 prospectively evaluated patients. Clin Microbiol Infect 2017; 23:406.e1.</a></li><li><a class="nounderline abstract_t">Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391:668.</a></li><li><a class="nounderline abstract_t">Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</a></li><li class="breakAll">Clinical Laboratory Standards Institute. Performance Standards for Susceptibility Testing. Twenty-seventh informational supplement CLSI document M100-S29. Wayne, PA 2019.</li><li><a class="nounderline abstract_t">Matsumoto JY, Wilson WR, Wright AJ, et al. Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother 1980; 18:944.</a></li><li><a class="nounderline abstract_t">Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98:2936.</a></li><li><a class="nounderline abstract_t">Farber BF, Eliopoulos GM, Ward JI, et al. Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother 1983; 24:871.</a></li><li><a class="nounderline abstract_t">Enzler MJ, Rouse MS, Henry NK, et al. In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis. J Infect Dis 1987; 155:954.</a></li><li><a class="nounderline abstract_t">Chow VC, Hawkey PM, Chan EW, et al. High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. Antimicrob Agents Chemother 2007; 51:2508.</a></li><li><a class="nounderline abstract_t">Farber BF, Yee Y. High-level aminoglycoside resistance mediated by aminoglycoside-modifying enzymes among viridans streptococci: implications for the therapy for endocarditis. J Infect Dis 1987; 155:948.</a></li><li><a class="nounderline abstract_t">Pericàs JM, Nathavitharana R, Garcia-de-la-Mària C, et al. Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">García-de-la-Mària C, Pericas JM, Del Río A, et al. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. Antimicrob Agents Chemother 2013; 57:2319.</a></li><li><a class="nounderline abstract_t">Cañas MA, Téllez A, García de la Mària C, et al. Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis. Antimicrob Agents Chemother 2021; 65:e0252220.</a></li><li><a class="nounderline abstract_t">Garcia-de-la-Maria C, Xiong YQ, Pericas JM, et al. Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Kebriaei R, Rice SA, Stamper KC, et al. Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Beganovic M, Luther MK, Rice LB, et al. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clin Infect Dis 2018; 67:303.</a></li><li><a class="nounderline abstract_t">Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.</a></li><li><a class="nounderline abstract_t">Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261.</a></li><li><a class="nounderline abstract_t">Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014; 20:O1075.</a></li><li><a class="nounderline abstract_t">Lorenzo MP, Kidd JM, Jenkins SG, et al. In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium. J Antimicrob Chemother 2019; 74:2269.</a></li><li><a class="nounderline abstract_t">Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995; 39:1984.</a></li><li class="breakAll">Eliopoulos GM. Enterococcal endocarditis. In: Infective Endocarditis, Kaye D (Ed), Raven Press, New York 1992. p.209.</li><li><a class="nounderline abstract_t">Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993; 7:117.</a></li><li><a class="nounderline abstract_t">Rice LB, Calderwood SB, Eliopoulos GM, et al. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991; 13:1.</a></li><li><a class="nounderline abstract_t">Olaison L, Schadewitz K, Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34:159.</a></li><li><a class="nounderline abstract_t">Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127:1810.</a></li><li><a class="nounderline abstract_t">GERACI JE, MARTIN WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954; 10:173.</a></li><li><a class="nounderline abstract_t">Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120:S28.</a></li><li><a class="nounderline abstract_t">Hindler JA, Wong-Beringer A, Charlton CL, et al. In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Antimicrob Agents Chemother 2015; 59:4279.</a></li><li><a class="nounderline abstract_t">Smith JR, Barber KE, Raut A, et al. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2015; 70:1738.</a></li><li><a class="nounderline abstract_t">Smith JR, Barber KE, Raut A, Rybak MJ. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother 2015; 59:2842.</a></li><li><a class="nounderline abstract_t">Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002; 35:902.</a></li><li><a class="nounderline abstract_t">Meyer DJ, Gerding DN. Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group. Am J Med 1988; 85:104.</a></li><li><a class="nounderline abstract_t">Murray BE, Karchmer AW, Moellering RC Jr. Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med 1980; 69:838.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Q fever: Information for Healthcare Providers. Available at: https://www.cdc.gov/qfever/healthcare-providers/index.html. (Accessed on November 30, 2022).</li><li><a class="nounderline abstract_t">Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Hasse B, Hannan MM, Keller PM, et al. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass. J Hosp Infect 2020; 104:214.</a></li></ol></div><div id="topicVersionRevision">Topic 2141 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320109" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33733675" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30152252" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474277" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519677" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6556711" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6556710" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6635444" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Therapy for experimental endocarditis due to Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706879" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36408468" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23857547" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389255" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389250" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Editorial commentary: surgical therapy for Staphylococcus aureus prosthetic valve endocarditis: proceed with caution (Caveat Emptor).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647736" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14765345" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109947" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444563" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017183" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cubicin resistance should be closely monitored in bacteremia patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1810196" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2128441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327776" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16283218" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6838067" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27615722" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia-a post hoc analysis in 964 prospectively evaluated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29249276" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086858" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086858" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235680" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860802" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnosis and management of infective endocarditis and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6559052" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3644854" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371822" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3644853" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High-level aminoglycoside resistance mediated by aminoglycoside-modifying enzymes among viridans streptococci: implications for the therapy for endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182540" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478959" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34252304" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264848" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962347" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29390132" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438316" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392394" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040215" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050740" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540703" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540703" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Aminoglycoside resistant enterococcal endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2017607" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Enterococcal endocarditis: a comparison of prosthetic and native valve disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740702" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543002" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13182750" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904948" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963982" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : In vitro activity of daptomycin in combination withβ-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645208" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753639" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12228838" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3291611" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446550" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446550" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535757" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715282" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
